← Back to Search

Tyrosine Kinase Inhibitor

Dasatinib for Fallopian Tube Cancer

Phase 2

Waitlist Available

Led By David M Hyman

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial looks at whether dasatinib can shrink tumors in patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.

Eligible Conditions

Ovarian Carcinoma
Fallopian Tube Cancer
Peritoneal Carcinoma
Endometrial Cancer
Ovarian Cancer
Endometrial Adenocarcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1

Secondary outcome measures

Duration of Overall Survival (OS)

Duration of Progression-free Survival (PFS)

Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0

Other outcome measures

ARID1A Mutation Status in Formalin-fixed, Paraffin Embedded Tissue Using Next-generation Exon-capture Sequencing

Side effects data

From 2022 Phase 2 trial • 54 Patients • NCT03023046

26%

Febrile neutropenia

17%

Sepsis

Mucositis oral

Upper gastrointestinal hemorrhage

Intracranial hemorrhage

Hypotension

Hypertension

Enterocolitis

Lower gastrointestinal hemorrhage

Delirium

Oropharyngeal pain

Gastric hemorrhage

Abdominal pain

Diarrhea

Fungemia

Typhlitis

Myocardial infarction

Fibrinogen decreased

Endophthalmitis

Multi-organ failure

Kidney infection

Peripheral motor neuropathy

Hypoxia

Sinus bradycardia

Edema limbs

Small intestinal obstruction

Atrial fibrillation

Aspiration

100%

80%

60%

40%

20%

Study treatment Arm

Treatment (Chemotherapy)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (dasatinib)Experimental Treatment2 Interventions

Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dasatinib

2012

Completed Phase 3

~2320

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NRG OncologyOTHER

231 Previous Clinical Trials

100,817 Total Patients Enrolled

National Cancer Institute (NCI)Lead Sponsor

13,654 Previous Clinical Trials

40,933,118 Total Patients Enrolled

David M HymanPrincipal InvestigatorNRG Oncology

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which hospitals are participating in this clinical study?

"This research is being conducted at Ascension Saint Vincent Indianapolis Hospital, Carle Cancer Center, Kuakini Medical Center, and 100 additional hospitals."

Answered by AI

How many test subjects are involved in this research project?

"This study has stopped recruiting patients. The listing was created on February 3rd, 2014 and last updated on September 16th, 2022. If you are looking for similar studies, there are currently 3405 clinical trials actively recruiting patients with recurrent ovarian carcinoma and 66 Dasatinib trials enrolling participants."

Answered by AI

Are there any know serious side effects of taking Dasatinib?

"Dasatinib is classified as a Phase 2 drug, meaning that while there is evidence of safety, there is no concrete data supporting its efficacy. Our team at Power have given it a score of 2."

Answered by AI

Are there any patients that this research team is still looking to enroll?

"This specific study is no longer looking for patients, as it was last updated on September 16th, 2022. However, there are presently 3405 studies actively enrolling patients with recurrent ovarian carcinoma and 66 trials for Dasatinib which still need participants."

Answered by AI

What is the Dasatinib research landscape?

"Dasatinib is being researched in 66 ongoing medical studies, 9 of which are in the final Phase 3. Many of these trials are based out of New york City, but there are 4260 total locations across the globe running Dasatinib trials."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

2014. "Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02059265.